BioSpace

BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs

BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for both Opdivo and Eliquis.

作者 BioSpace

1 分钟阅读
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察